首页|CAV1在消化道肿瘤中的研究进展

CAV1在消化道肿瘤中的研究进展

扫码查看
消化道肿瘤是目前全球最常见的癌症之一,包括食管癌、胃癌、肝癌、胰腺癌和结直肠癌等,其预后不佳,治疗方法仍需进一步改进.小窝蛋白-1(caveolin-1,CAV1)在消化道肿瘤中具有双重调节作用,既是肿瘤抑制因子又是致癌因子.CAV1对消化道肿瘤的细胞增殖、侵袭、转移、血管生成和药物耐受性等方面具有重要作用,调节CAV1蛋白及其相关信号通路可能成为治疗消化道肿瘤的策略之一.因此,本综述就CAV1的结构、功能、表达调控以及调节消化道肿瘤上皮-间充质转换(epithelial-mesenchymal transition,EMT)及其耐药性等方面分析CAV1与消化道肿瘤的关系,以期为临床消化道肿瘤的诊疗提供新的思路.
Advances in the study of CAV1 in digestive tract tumors
Digestive tract tumors are currently one of the most common types of cancer,including esophageal cancer,gastric cancer,hepatocellular carcinoma,pancreatic cancer,and colorectal cancer.Their prognoses are poor and the treatments require further improvement.Caveolin-1(CAV1)has a dual regulatory effect on digestive tract tumors as a tumor suppressor and cancer promoter.CAV 1 plays a major role in cell proliferation,invasion,metastasis,angiogenesis,and drug tolerance of digestive tract tumors.The regulation of CAV1 protein and its related signaling pathways may be a strategy for the treatment of digestive tract tumors.This review analyzes the relationship between CAV 1 and digestive tract tumors in terms of structure,function,expression regulation,regulation of epithelial-mesenchymal transition,and drug resistance in digestive tract tumors to provide new ideas for the diagnosis and treatment of digestive tract tumors.

CAV 1digestive tract tumorEMTdrug resistance

吴志航、唐明政、李晓凤、荣耀、崔岩、潘海邦

展开 >

甘肃中医药大学第一临床医学院,甘肃省中药新产品创制工程实验室,甘肃省中医方药挖掘与创新转化重点实验室,兰州 730000

CAV1 消化道肿瘤 EMT 耐药

国家自然科学基金甘肃省高等学校创新基金

818608502023A-076

2024

中国比较医学杂志
中国实验动物学会,中国医学科学院医学实验动物研究所

中国比较医学杂志

CSTPCD北大核心
影响因子:0.473
ISSN:1671-7856
年,卷(期):2024.34(7)